The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2023 | CAR-T therapy vs BiTEs in multiple myeloma: current outlooks & the importance of patient selection
In this video, Ciprian Tomuleasa, MD, PhD, University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania, comments on how the treatment of multiple myeloma has changed over the years with the introduction of novel immunotherapies, including CAR-T cells and bispecific antibodies. Dr Tomuleasa also highlights the importance of optimizing patient selection for these agents. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
